Olema Pharmaceuticals Inc (OLMA) Stock Price, Quote & News

Company Profile

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivota...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 651 3316

Website: olema.com

Address:

780 Brannan Street, San Francisco, United States

d_risk Nov. 10 at 4:25 PM

$OLMA - Olema Pharmaceuticals Inc. Common Stock - 10Q - Updated Risk Factors OLMA’s latest 10-Q risk factors highlight heightened financial and geopolitical pressures, expanded cybersecurity and global trade risks, new and detailed intellectual property litigation and patent uncertainties, increased challenges in international expansion, and the removal of prior risks on employee misconduct and animal testing. #Pharmaceuticals #IntellectualProperty #Cybersecurity #GeopoliticalRisk #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/OLMA/10-Q/2025-11-10

0 · Reply

ContrarianMoves Nov. 5 at 1:00 PM

$OLMA they declare bankruptcy?

0 · Reply

AnyaGirl Nov. 4 at 12:52 PM

$OLMA Why is this dropping to 0???

0 · Reply

Rudy2314 Oct. 31 at 10:19 PM

$OLMA $12 plus next week… data is 2 good!

0 · Reply

OpenOutcrier Oct. 31 at 12:49 PM

$OLMA (+7.1% pre) Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 https://ooc.bz/l/82841

0 · Reply

Surenp Oct. 31 at 10:29 AM

$OLMA good time to buy

0 · Reply

BearTamerTrading Oct. 30 at 10:10 PM

🚀 After-Hours Catalyst Movers — Bear Tamer Trading 💥 The plays were called live before the move — here’s what lit the fuse: 🔥 $CERO — Granted FDA Orphan Drug Designation + Phase 1 AML trial initiation for CER-1236. Being Delisted. 🔥 $DLHC — Insider buying signals + major government contract award potential looming. 🔥 $OLMA — Preclinical data release for OP-3136 with anti-tumor activity + Phase 1/2 expansions underway. 🔥 $NCEL — Strategic merger with Kadimastem, advancing IND-enabling studies for AEX-2/AEX-41 (CNS/neurodegenerative focus). 🔥 $ARDX — Commercial momentum update for IBSRELA/XPHOZAH + upcoming pediatric/expansion catalysts. Members were already in position before the volume spike 💪 If you missed it, watch the replay for proof — testimonials are in the comments ⬇️ 🎥 Replay: https://www.youtube.com/live/xdUKEXgJR0c?si=llCNifrUpufVHyzM

0 · Reply

theBigDollarski Oct. 30 at 10:03 PM

$OLMA lotsa action ah..what gives?

1 · Reply

BearishAlgo Oct. 30 at 9:34 PM

$OLMA same with this ticker, had a major resistance above $12, and Phase 3 trial news, but technical resistance won here too (I'm talking about intraday setups)

0 · Reply

dixiebull Oct. 30 at 9:21 PM

gotta love $OLMA

0 · Reply

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Nov 4, 2025, 4:30 PM EST - 10 days ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 3, 2025, 4:30 PM EST - 11 days ago

Olema Oncology to Participate in Upcoming Investor Conferences

Oct 30, 2025, 4:30 PM EDT - 15 days ago

Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025

Oct 30, 2025, 3:25 PM EDT - 15 days ago

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Oct 18, 2025, 3:00 AM EDT - 4 weeks ago

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Sep 2, 2025, 7:00 AM EDT - 2 months ago

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

PFE

Aug 11, 2025, 4:01 PM EDT - 3 months ago

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

May 28, 2025, 7:00 AM EDT - 6 months ago

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

May 13, 2025, 4:01 PM EDT - 6 months ago

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

Apr 25, 2025, 1:00 PM EDT - 7 months ago

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

Apr 8, 2025, 4:25 PM EDT - 7 months ago

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Mar 25, 2025, 4:31 PM EDT - 8 months ago

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Mar 18, 2025, 4:01 PM EDT - 8 months ago

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 18, 2025, 7:00 AM EST - 9 months ago

Olema Oncology Appoints Shawnte M. Mitchell, J.D.

Jan 2, 2025, 7:00 AM EST - 11 months ago

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 7:46 AM EST - 11 months ago

Top 3 Health Care Stocks That May Explode In Q4

SLN

Dec 10, 2024, 7:00 AM EST - 1 year ago

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Dec 9, 2024, 7:00 AM EST - 1 year ago

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Nov 25, 2024, 5:30 PM EST - 1 year ago

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Nov 12, 2024, 4:01 PM EST - 1 year ago

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 6, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 28, 2024, 7:03 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in June

May 15, 2024, 7:01 AM EDT - 1 year ago

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

May 8, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

May 1, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in May

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

Mar 11, 2024, 4:03 PM EDT - 1 year ago

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 7:03 AM EST - 1 year ago

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Jan 8, 2024, 8:12 AM EST - 2 years ago

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Jan 3, 2024, 8:29 AM EST - 2 years ago

Olema Pharmaceuticals: Oral SERD Developer With Interesting Data

Jan 2, 2024, 4:01 PM EST - 2 years ago

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 12:27 PM EST - 2 years ago

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Nov 28, 2023, 5:10 PM EST - 2 years ago

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

Nov 28, 2023, 11:52 AM EST - 2 years ago

Olema Pharmaceuticals: Advancing On Multiple Fronts

Nov 7, 2023, 4:02 PM EST - 2 years ago

Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 1, 2023, 4:27 PM EDT - 2 years ago

Olema Oncology to Participate in Upcoming Investor Conferences in November

Oct 22, 2023, 2:55 AM EDT - 2 years ago

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

Oct 17, 2023, 7:01 AM EDT - 2 years ago

Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

Oct 16, 2023, 7:02 AM EDT - 2 years ago

Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

Oct 12, 2023, 7:01 AM EDT - 2 years ago

Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

Sep 20, 2023, 7:29 AM EDT - 2 years ago

Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 3:20 PM EDT - 2 years ago

Olema: Two-Pronged Approach To Treat Breast Cancer Patients

Sep 5, 2023, 7:30 AM EDT - 2 years ago

Olema Oncology Announces Combined Financing for Up to $180 Million

Aug 8, 2023, 4:03 PM EDT - 2 years ago

Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference

d_risk Nov. 10 at 4:25 PM

0 · Reply

ContrarianMoves Nov. 5 at 1:00 PM

$OLMA they declare bankruptcy?

0 · Reply

AnyaGirl Nov. 4 at 12:52 PM

$OLMA Why is this dropping to 0???

0 · Reply

Rudy2314 Oct. 31 at 10:19 PM

$OLMA $12 plus next week… data is 2 good!

0 · Reply

OpenOutcrier Oct. 31 at 12:49 PM

$OLMA (+7.1% pre) Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 https://ooc.bz/l/82841

0 · Reply

Surenp Oct. 31 at 10:29 AM

$OLMA good time to buy

0 · Reply

BearTamerTrading Oct. 30 at 10:10 PM

0 · Reply

theBigDollarski Oct. 30 at 10:03 PM

$OLMA lotsa action ah..what gives?

1 · Reply

BearishAlgo Oct. 30 at 9:34 PM

$OLMA same with this ticker, had a major resistance above $12, and Phase 3 trial news, but technical resistance won here too (I'm talking about intraday setups)

0 · Reply

dixiebull Oct. 30 at 9:21 PM

gotta love $OLMA

0 · Reply

TwongStocks Oct. 30 at 8:32 PM

$OLMA Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 https://ir.olema.com/news-releases/news-release-details/olema-oncology-present-trial-progress-poster-phase-3-opera-02 Poster Presentation Details Title: OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer Abstract Number: 264 Presentation Number: PS5-12-18 Date/Time: Friday, December 12, 2025 from 12:30pm–2:00pm CT / 1:30pm–3:00pm ET

0 · Reply

OptionRunners Oct. 30 at 7:29 PM

$OLMA CNBC pro long idea "Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here"

0 · Reply

theBigDollarski Oct. 21 at 11:59 AM

$OLMA i was waiting for a pullback and got it..I'm in

0 · Reply

DaBullRunner Oct. 20 at 8:29 PM

BYND there it goes… TOLD YOU👇🤑💰🤑💰🤑 RVP adding this before the crowd arrives 🚨🚨🚨 Adding with the CEO 🚢📦📦📦 This could be the next OPEN I’m telling you And I got in this EARLY $CHNR $JWEL $OLMA $OSRH $GIFT let’s get it

0 · Reply

Gabu Oct. 20 at 5:40 PM

$OLMA Market is discounting it and favoring Roche but the data is very positive.

0 · Reply

mikelet Oct. 20 at 1:28 PM

$OLMA I understand results are good for 120mg, isn't it?

2 · Reply

OpenOutcrier Oct. 20 at 12:23 PM

$OLMA (-30.1% pre) 15.5‑Month Median PFS — Olema Oncology's 120 mg palazestrant + ribociclib supports Phase 3 OPERA-02 https://ooc.bz/l/81151

0 · Reply

JarvisFlow Oct. 20 at 11:58 AM

HC Wainwright & Co. updates rating for Olema Pharmaceuticals ( $OLMA ) to Buy, target set at 28.

0 · Reply

justiceforb_85 Oct. 19 at 4:03 AM

$OLMA palezsatrant likely best-in-class and active in ESR1-WT patients.

1 · Reply

microeone Oct. 18 at 4:37 PM

$OLMA good data release albeit phase 1/2… continue to show pala might be best in class

1 · Reply

Quantumup Oct. 8 at 3:46 PM

Guggenheim🏁 $OLMA Buy/$20 $NVS $PFE $RHHBY Guggenheim said in it initiation report:

0 · Reply

FormFour Oct. 5 at 3:33 PM

$OLMA Healthcare technology. Testing key support. Volume pattern shows distribution. Growth concerns persisting.

0 · Reply

Market Cap	545.16M
Revenue (ttm)	0.00
Net Income (ttm)	-129.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.01

Volume	712,900
Avg Vol	1,257,420
Day's Range	N/A - N/A
Shares Out	68.66M
Stochastic %K	59%
Beta	2.07
Analysts	Strong Sell
Price Target	$24.38